Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT00164554 Completed - Clinical trials for Fetal Alcohol Syndrome

Fetal Alcohol Syndrome/ARND Research Consortion

Start date: October 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Children will receive comprehensive evaluations through the UOHSC ABC program The assessment for the child will include: medical issues (including medication), dysmorphic examination, intellectual assessment, academic achievement, language, and motor skills. This program will provide appropriate non-study services and referrals. Eligible families will be randomly assigned to treatment group or control group. Treatment group will receive Parent Child Interaction Therapy (PCIT). The Control group will receive standard referrals and services through the ABC program and the parent education/advocacy component of the project.

NCT ID: NCT00164229 Completed - Clinical trials for Fetal Alcohol Syndrome

Fetal Alcohol Syndrome: Socio-Cognitive Habilitation

Start date: October 2001
Phase: Phase 1/Phase 2
Study type: Interventional

Comprehensive evaluation (geneticist, psychologist, social worker, education specialist, others as indicated) to determine individual needs and treatment plan. Referrals for specific services (e.g., OT, counseling, medications, etc) will be to clinicians within the families' own communities. All families will receive evaluation, parent education/advocacy, and learning readiness program. Only the intervention group will receive the math intervention.

NCT ID: NCT00163943 Recruiting - Clinical trials for Metabolic Syndrome X

Sympathetic Activity in Individuals With the Metabolic Syndrome: Benefits of Lifestyle Interventions

Start date: April 2005
Phase: N/A
Study type: Interventional

An abdominal distribution of fat is associated with the greatest heart disease risk, because commonly, several risk factors of metabolic origin (high blood pressure, unfavourable cholesterol profile, elevated blood sugar, impaired insulin action) cluster in these individuals. When this occurs the condition is called the 'metabolic syndrome' (MetS). The cause of the MetS is yet to be fully elucidated. Increased activity of the nervous system resulting in enhanced release of the stress hormone 'norepinephrine', may be one mechanism by which adverse cardiovascular and metabolic sequelae of the MetS might be mediated. Dietary weight loss, and exercise are first-line treatments for the MetS and provide an opportunity to prevent or delay the development of type 2 diabetes and heart disease in this high risk group. However, there is a paucity of data regarding the effects of these lifestyle factors on the nervous system. Furthermore, it is also unknown whether active weight loss ('negative energy balance') or a stable lower weight (weight loss maintenance) is more important in modifying MetS components and nervous system activity. The aims of the proposed project are: 1. To determine whether dietary weight loss in combination with aerobic exercise is more beneficial than dietary weight loss alone in reducing nervous system activity and improving metabolic and cardiovascular parameters in middle-aged men and women with abdominal obesity and the MetS. 2. To determine whether weight loss maintenance four months after active weight loss is associated with a preservation of clinical benefits. 3. To study biological determinants of successful weight loss and weight loss maintenance.

NCT ID: NCT00161538 Completed - Sick Sinus Syndrome Clinical Trials

Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation

Start date: July 2000
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine which of 4 lead positions is most effective for pacemaker patients with Sick Sinus Syndrome in order to avoid development of atrial fibrillation.

NCT ID: NCT00161109 Recruiting - Clinical trials for Chromosome 22q11.2 Deletion Syndrome

Genetics and Psychopathology in the 22q11 Deletion Syndrome

Start date: October 2002
Phase: N/A
Study type: Observational

The purposes of this study are to: 1. study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and 2. identify genes that contribute to the occurrence of these symptoms.

NCT ID: NCT00160355 Completed - Clinical trials for Wiskott-Aldrich Syndrome

Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome

Start date: May 2005
Phase: Phase 1
Study type: Interventional

Wiskott - Aldrich syndrome (WAS) is a rare disorder curable only through allogeneic hematopoietic stem cell transplantation. A mismatched family member is an option when no human leukocyte antigen (HLA-immune system type) matched related or matched unrelated donor is available. This study will evaluate a novel therapeutic strategy for patients with WAS who undergo haploidentical transplantation using a parental donor. To reduce the risk of transplant-related toxicities, participants will receive a reduced intensity chemotherapy and antibody regimen (conditioning treatment). Participants will then receive an infusion of donor stem cells depleted of certain white blood cells called T- and B-lymphocytes. The stem cell depletion processing will be done through the use of the investigational CliniMACS device. A certain number of T-lymphocytes will be added back to the processed stem cell graft prior to infusion into the recipient. The primary objective of this study is to determine the safety of haploidentical transplantation in WAS patients using this specified conditioning regimen and engineered graft. Safety will be defined in terms of engraftment (meaning how well the graft grows and functions after infusion) and regimen-related toxicity within the first 100 days after transplant.

NCT ID: NCT00160082 Completed - Clinical trials for Post Polio Syndrome, PPS

Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)

Start date: January 2001
Phase: N/A
Study type: Interventional

The primary objective was to assess the effect of Xepol compared to placebo on physical health and on muscle strength in subjects with post-polio syndrome.The secondary objective was to assess the effect of Xepol compared to placebo on functional balance, activity patterns, pain, fatigue, sleep, vitality, muscular strength, pulmonary capacity, walking ability, balance and safety.

NCT ID: NCT00159536 Completed - Clinical trials for Polycystic Ovary Syndrome

Metformin in Pregnant PCOS Women

PregMet
Start date: February 2005
Phase: Phase 3
Study type: Interventional

To investigate the effect of metformin on pregnancy complications and pregnancy outcome in the II. and III. trimester of pregnancy in women with polycystic ovary syndrome.

NCT ID: NCT00157274 Recruiting - Mycosis Fungoides Clinical Trials

Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The investigators designed a compassionate basis phase II study for refractory/relapsed mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation of overall response and time to relapse. Other goals to consider are toxicity and time to new therapy.

NCT ID: NCT00156455 Withdrawn - Clinical trials for Obstructive Sleep Apnea Syndrome

Sleep Disordered Breathing in Children With Single Ventricle Physiology

Start date: September 2004
Phase: N/A
Study type: Observational

This is an exploratory study designed to evaluate the incidence of, and to quantify sleep disordered breathing following stage I Norwood reconstructive surgery. Sleep disordered breathing will be correlated with: 1. Elevations in pulmonary vasculature resistance at the time of Stage II surgery. 2. Risks of death